You are here:

atazanavir (Reytaz)


Following an abbreviated submission:      

atazanavir 150, 200 and 300mg capsules (Reyataz): is accepted for use in NHSScotland.      

Indication under review: atazanavir, co-administered with low dose ritonavir, is indicated for the treatment of paediatric patients 6 years of age and older in combination with other antiretroviral medicinal products.

Data available in children aged 6 to less than 18 years are very limited.  Available data suggest that atazanavir in combination with ritonavir may not be effective in treatment experienced children even with very few (<3) protease inhibitor mutations.  The choice of atazanavir in treatment experienced paediatric patients should be based on individual viral resistance testing and the patient’s treatment history.

The Scottish Medicines Consortium has previously accepted this product for use in HIV infection in adults.  Atazanavir is listed in the British National Formulary for Children 2010 -11 for the treatment of HIV.

Drug Details

Drug Name: atazanavir (Reytaz)
SMC Drug ID: 656/10
Manufacturer: Bristol-Myers Squibb Pharmaceuticals Ltd
Indication: Treatment of paediatric patients 6 years of age and older in combination with other antiretroviral medicinal products
BNF Category:
Sub Category: 5.3 Antiviral Drugs
Submission Type: Abbreviated Submission
Status: Accepted
Date Advice Published: 13 December 2010